Research Updates in Gout: Improving Response Rate to Therapy

To participate in this activity, please:

Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence related to gout, as well as study results presented at the American College of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger begins with an introduction on a recent published systematic review indicating that the manifestations of gout extend beyond the joints, affecting other organs and tissues. Dr. Schlesinger also provides an overview of some of the challenges encountered in clinical practice with the use of urate-lowering therapy. Dr. Schlesinger focuses on two abstracts concerning gout-related comorbidities, particularly cardiovascular disease. Dr. Mandell focus on two abstracts related to the safety and use of urate-lowering therapy, specifically allopurinol, febuxostat, and pegloticase. Dr. Mandell also discuss 2 abstracts related to the systemic nature of gout; one abstract focuses on heart failure, while the other focuses on the lumbar spine. Finally, Dr. Mandell discuss the RECIPE trial recently published in 2021 that focuses on the use of immunomodulatory therapy to reduce the immunogenicity associated with pegloticase. So, on behalf of Dr. Schlesinger, I invite you to join us for this CME activity on research updates in gout.

Course Credit:

1.00 AMA PRA Category 1 CreditTM


Opens: 2021-01-22
Closes: 2022-01-22

Target Audience:

This activity was developed for rheumatologist, nephrologists, and other healthcare professionals involved in the care of patients with gout.

This activity is supported by an independent educational grant from Horizon Therapeutics.

    Presenting Faculty

  • Brian Mandell, MD, PhD

    Professor of Medicine
    Chairman of Academic Medicine
    Cleveland Clinic
    Cleveland, OH

  • Naomi Schlesinger, MD

    Professor of Medicine Chief, Division of Rheumatology
    Rutgers-Robert Wood Johnson Medical School
    New Brunswick, New Jersey

Learning Objectives

  • Summarize the latest evidence related to combination pharmacologic treatment of patients with gout who do not achieve the target serum urate level with monotherapy
  • Summarize the latest evidence related to complications associated with gout
  • Incorporate evidence-based research into clinical practice

Faculty Disclosures

Brian Mandell, MD, PhD

Consultant: Horizon

Data Monitoring Safety Board: Horizon

Speakers Bureau: Genentech  

Naomi Schlesinger, MD

Advisory Board: IFM, Johnson and Johnson

Research Support: Amgen, Pfizer

Speakers Bureau: Horizon

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.